IntraOp Announces Two New Mobetron Orders In China

Main Category: Cancer / Oncology
Article Date: 20 Jul 2009 - 3:00 PDT

email to a friend   printer friendly   opinions  

IntraOp Medical Corporation (OTCBB: IOPM), a provider of Intra-Operative Electron-beam Radiation Therapy (IOERT) solutions for the treatment and eradication of cancer, announced today two new orders for its Mobetron system from its Chinese distribution partner, Hui Long New Technology Co. LTD.

IntraOp's Mobetron is a mobile technology that delivers IOERT to a tumor site during cancer surgery. The Mobetron enables radiation and surgical oncologists to pinpoint the optimal site for radiation and to deliver an effective dose during the procedure. Since the Mobetron is a mobile, self-shielded device, doctors are able to move the Mobetron among operating rooms (ORs) to treat a greater number of patients more effectively, efficiently and cost-effectively than with a conventional linear accelerator.

This order marks the fifth and sixth Mobetrons sold in China. In the twelve months since installing and utilizing the first device, oncologists in China have had notable success with IOERT, inspiring other centers to follow suit. Earlier this year, IntraOp sold and shipped Mobetrons to two Shanghai medical facilities, where they are currently being installed. This most recent order of two Mobetrons is for hospitals that should be ready for installation early next year. The order reflects Hui Long's optimism about the near-term opportunities for Mobetron sales in China.

Peter Yu, IntraOp's Director of Far East Operations, noted, "With the very high patient loads our oncologists experience here in China, IOERT is often the only way to ensure that some patients are getting the radiation therapy treatment they need in a reasonable amount of time. With this order, we will be able to satisfy our customers' growing demand for a device that will enable them to deliver IOERT in the OR."

IntraOp CEO John Powers added, "This order represents our fifth and sixth Mobetron sale in China in just 18 months. This adoption rate demonstrates China's willingness to leap frog old technologies, while quickly adopting and standardizing on new technologies proven to provide superior outcomes. We are incredibly optimistic about this adoption rate and the Mobetron's potential to benefit cancer patients."

Source
IntraOp Medical Corporation

• Additional
• References
• Citations